(Yicai) Jan. 3 -- US pharmaceutical company Gilead Sciences has been given the greenlight by Chinese regulators to sell its ...

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...

Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility.

Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...

Emerging data suggest that antiviral therapy in the third trimester can ... Pan has received research grants from Gilead, Bristol Myers Squibb, Novartis, and Roche. He also serves as a consultant ...

We came across a bullish thesis on Gilead Sciences, Inc. (NASDAQ:GILD) on Substack by Magnus Ofstad. In this article, we will ...

Shares of Assembly Biosciences (NASDAQ:ASMB) traded higher on Thursday after Gilead Sciences (NASDAQ:GILD) agreed to increase its ownership in the antiviral developer to 29.9% following an equity ...

(RTTNews) - Assembly Biosciences, Inc. (ASMB), Thursday announced that the company has received a total of $30.1 million from Gilead Sciences ... clinical pipeline of antiviral therapeutic ...

(RTTNews) - Gilead Sciences, Inc. (GILD) Tuesday said that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adults with ...

She has also served as a consultant and advisor for Gilead. Assessment of antiviral therapy and monitoring in mothers at the phase of immune tolerance or inactive carrier. ALT, alanine ...